Analysts: Oracle Opens Up Buying Opportunity and 4 New Opinions Investors Must Pore Over

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS): According to BMO Capital, data from a Phase I test of Isis’ and Biogen’s (NASDAQ:BIIB) ISIS-SMN-Rx, an antisense oligonucleotide, for children with spinal muscular atrophy, may indicate that the drug has a substantial clinical benefit. The firm decided to keep its Outperform rating and increase its price target to $22 from $17 on the stock

The stock market is at 5-year highs! Discover the best stocks to buy in today’s market. CLICK HERE for Your Stock Investor Cheat Sheet NOW!

ISIS